H.R. 10359: Priority for Pediatric Cures Act

This bill would make a small but important change to federal drug law: it would permanently continue the government’s authority to give priority review vouchers for drugs and biologics developed for rare pediatric diseases.

What that means

Under current law, a company that develops an approved treatment for a qualifying rare disease in children can receive a voucher from the Food and Drug Administration (FDA). That voucher can be used later to speed up FDA review of another drug application, or it can be sold or transferred to another company. These vouchers are intended to encourage companies to invest in treatments for very small patient populations that might otherwise be less commercially attractive.

What this bill would change

The bill would remove the current expiration on this authority. In practical terms, it would:

• Keep the rare pediatric disease priority review voucher program in place permanently, rather than letting it lapse under the existing sunset date.
• Continue allowing qualifying companies to earn vouchers after bringing certain rare pediatric disease products to market.
• Maintain the ability to use or sell those vouchers as a way to offset the time and cost of drug development.

What would not change

The bill does not change the FDA’s standards for approving drugs, and it does not itself approve any specific medicine. It also does not directly alter how much a drug costs, what diseases qualify, or how the vouchers are used beyond making the program permanent.

Potential effect

If enacted, the bill would provide longer-term certainty to drug developers working on treatments for rare diseases in children. Supporters of the underlying program typically view the vouchers as one way to help bring more pediatric rare-disease treatments to patients. The bill itself is limited to extending the program’s duration.

Relevant Companies

• None found